Product Code: RP-ID-10325832 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10325832
Market Overview:
Global Leukemia Therapeutics Market – By Disease Type (Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, and Acute Myeloid Leukemia), By Drug Class (Small Molecules and Biologics), and By Regions (North America, Europe, Asia Pacific, and Rest of the World): Forecast up to 2025
Global Leukemia Therapeutics Market – By Disease Type (Chronic Myeloid
Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, and
Acute Myeloid Leukemia), By Drug Class (Small Molecules and Biologics), and By
Regions (North America, Europe, Asia Pacific, and Rest of the World): Forecast up
to 2025
This market research report includes a detailed segmentation of the global
leukemia therapeutics market by disease type (chronic myeloid leukemia, chronic
lymphocytic leukemia, acute lymphocytic leukemia, and acute myeloid leukemia), by
drug class (small molecule and biologics), and by regions (North America, Europe,
Asia Pacific, and Rest of the World).
Overview of the Global Leukemia Therapeutics Market Research:
Infoholic’s market research report predicts that the global leukemia therapeutics
market will grow at a CAGR of 6.2% during the forecast period 2019–2025. Leukemia
refers to the group of blood cancer that usually develops in the bone marrow,
resulting in the formation of abnormal blood cells. Leukemia is subdivided into
lymphoblastic or lymphocytic leukemias and myeloid or myelogenous leukemias
that include acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL),
chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).
The upsurge in the incidence of leukemia cases across the globe, rising elderly
population, and the advent of innovative therapies are among the factors driving
the market growth. In the US, an estimated 61,780 people were expected to be
diagnosed with leukemia in 2019. Approximately 10,670 people died of AML in 2018.
In Europe, nearly 30,000 people had CLL in 2018. Leukemia was the 8th most
commonly diagnosed cancer in Australia with 3,905 cases in 2015 and it is estimated
that leukemia will remain the 8th most commonly diagnosed cancer in 2019.
However, strict regulatory guidelines, increased cost of the drug, and side effects
associated with drugs are few of the factors that may prove detrimental to the
market. Growing investment in R&D for the development of the new drugs,
promising pipeline, and opportunities in emerging economies are anticipated to
enhance the revenue of the leukemia therapeutics market in the next five years.
•Promisingpipelineofleukemiadrugs•OpportunitiesinemergingeconomiesOpportunities
Risk•Highcostofthedrugs•Strictregulatoryguidelines
Drivers•Increasing incidence of leukemia cases across the globe•Rising elderly population
Market dynamics
Thekeymarketplayersuseproductapprovalasoneofthekeystrategiestostrengthentheirpositioninthemarket.Forinstance,inApril2018,PfizerInc.receivedEuropeanCommissionapprovalforMYLOTARGincombinationwithdaunorubicinandcytarabine,whichisthefirstandonlyAMLtherapyapprovedintheEUthattargetsCD33.CAGR of 6.2%: 2019–2025
CAGR >7.5%
The industry generates the majority of the revenue from the key players operating
in this field; few of them include Novartis AG, F-Hoffmann-La Roche Ltd., Pfizer Inc.,
Sanofi S.A., Bristol–Myers Squibb Company, and AbbVie Inc.
According to the Infoholic Research analysis, North America accounted for the
largest share of the global leukemia therapeutics market in 2018 and will retain a
high position during the forecast period. North America is followed by Europe with a
share of more than 25% of the global market in 2018.
By Disease Type:
ï‚· Chronic Myeloid Leukemia (CML)
ï‚· Chronic Lymphocytic Leukemia (CLL)
ï‚· Acute Lymphocytic Leukemia (ALL)
ï‚· Acute Myeloid Leukemia (AML)
In 2018, the chronic myeloid leukemia segment accounted for the largest share and
is expected to grow at a mid-single-digit CAGR by 2025. The high prevalence rate of
CML and the availability of a huge number of treatment choices make the segment
the largest shareholder in the global leukemia therapeutics market.
By Molecule Type:
ï‚· Small Molecules
ï‚· Biologics
Based on the molecule type analysis, the small molecules segment dominated the
market in 2018 with a share of over 75% and is expected to maintain this position
throughout the forecast period. Biologics is expected to grow at a high CAGR during
the forecast period 2019–2025.
By Regions:
ï‚· North America
ï‚· Europe
ï‚· Asia Pacific
ï‚· Rest of the World
Based on geography, North America dominated the market in 2018 with a share of
over 40% and is expected to grow at mid-single-digit CAGR during the forecast
period 2019–2025. The high incidence and prevalence rate of the disease, increasing
awareness on personalized medicine, and the existence of reputed players
extensively involved in the commercialization of branded therapeutics make the
region a dominant shareholder in the global leukemia therapeutics market. Asia
Pacific is projected to grow at a high CAGR during the forecast period 2019–2025.
Global Leukemia Therapeutics Market Research Competitive Analysis: The
market is growing at a steady rate with a CAGR of 6.2% during the forecast period
2019–2025. There are many new drug launches, approval, development, and
funding related to leukemia drugs owing to the increased patient base across the
globe. For instance, in 2019, Ivosidenib (TIBSOVO) developed by Agios
Pharmaceuticals, Inc. was approved by the FDA for the treatment of AML in older
patients with a susceptible IDH1 mutation who have comorbidities that preclude the
use of intensive induction chemotherapy. Astellas Pharma received FDA approval
for gilteritinib, in November 2018, the first-ever inhibitor drug explicitly approved for
treating patients with relapsed or refractory AML with a mutation in the FLT3 gene.
FDA granted a supplemental approval to acalabrutinib (Calquence) developed by
AstraZeneca to treat CLL or SLL in December 2019.
There is an increasing collaboration to develop novel leukemia therapeutics. For
instance, MD Anderson Cancer Center and Ascentage Pharma entered into a five-
year collaboration that aims to accelerate clinical development of novel apoptosis-
targeted and tyrosine kinase inhibitor drug candidates for leukemia treatment.
Key Vendors:
ï‚· Novartis AG
ï‚· F-Hoffmann-La Roche Ltd.
ï‚· Pfizer Inc.
ï‚· Sanofi S.A.
ï‚· Bristol–Myers Squibb Company
ï‚· AbbVie Inc.
ï‚· Amgen Inc.
ï‚· Takeda Pharmaceutical Company Limited
ï‚· Gilead Science Inc.
ï‚· GlaxoSmithKline
ï‚· Eisai Co. Ltd.
ï‚· Biogen Inc.
Key Competitive Facts:
ï‚· The pipeline of oncology drugs in the clinical development has expanded by
45% over the past 10 years; 87% of the late-stage pipeline is targeted
therapies, which include small molecule protein kinase inhibitors and biologic
monoclonal antibodies.
ï‚· Jazz Pharmaceuticals plc received European Commission approval for its
marketing authorization application for Vyxeos in August 2018 for the
treatment of newly diagnosed AML with myelodysplasia-related changes in
adult patients or therapy-related acute myeloid leukemia.
Benefits – The report provides complete details about the sub-segment of the
global leukemia therapeutics market. Thus, the key stakeholders can know about
the major trends, drivers, investments, vertical player’s initiatives, and government
initiatives toward the pharmaceutical segment in the upcoming years, along with
details of the pureplay companies entering the market. Moreover, the report
provides details about the major challenges that are going to impact the market
growth. Additionally, the report gives complete details about the key business
opportunities to key stakeholders in order to expand their business and capture the
revenue in specific verticals, and to analyze before investing or expanding the
business in this market.
Key Takeaways:
ï‚· Understanding the potential market opportunity with precise market size and
forecast data.
ï‚· Detailed market analysis focusing on the growth of the leukemia therapeutics
industry.
ï‚· Factors influencing the growth of the leukemia therapeutics market.
ï‚· In-depth competitive analysis of dominant and pure-play vendors.
ï‚· Prediction analysis of the leukemia therapeutics industry in both developed
and developing regions.
ï‚· Key insights related to major segments of the leukemia therapeutics market.
ï‚· Latest market trend analysis impacting the buying
Novartis AG
F-Hoffmann-La Roche Ltd.
Pfizer Inc.
Sanofi S.A.
Bristol–Myers Squibb Company
AbbVie Inc.
Amgen Inc.
Takeda Pharmaceutical Company Limited
Gilead Science Inc.
GlaxoSmithKline
Eisai Co. Ltd.
Biogen Inc.
Related Reports
Proof of Quality & Reliability
